Today: Dec 22, 2024
RU / EN
Last update: Oct 30, 2024
The Study of Synthesis, Accumulation and Release Processes of Atrial and Brain Natriuretic Peptides in Experimental Renovascular Hypertension

The Study of Synthesis, Accumulation and Release Processes of Atrial and Brain Natriuretic Peptides in Experimental Renovascular Hypertension

Galkina М.V., Baskina О.S., Bugrova М.L.
Key words: аtrial natriuretic peptide; brain natriuretic peptide; renovascular hypertension.
2015, volume 7, issue 2, page 33.

Full text

html pdf
2445
1811

The aim of the investigation was to study the dynamics of synthesis, accumulation and release processes of atrial (ANP) and brain (BNP) natriuretic peptides on day 60 of experimental renovascular hypertension.

Materials and Methods. The experiments were carried put on white non-pedigree male rats. We studied renovascular hypertension using a two-kidney model with the left renal artery ligation. Arterial pressure (AP) was measured via caudal artery using an invasive technique. We analyzed left ventricular cardiac myocyte areas by light optics. Electron microscopic investigation was applied to study the left ventricular and right atrial tissue samples. ANP and BNP accumulation and release processes were assessed using a quantitative analysis of immunolabeled granules of atrial myocytes (А-type, “mature, storing”, and B-type, “dissolving”) under the transmission electron microscope. We performed a morphometric analysis of morphological types of the left ventricular and right atrial mitochondria.

Results. The number of granules containing ANP and BNP in atrial myocytes on day 60 after the left renal artery ligation in rats was found to be no significantly different from that in the intact group. We revealed AP decrease up to the initial level. ANP and BNP content in atrial myocytes and AP recovered against the background of cardiac myocyte hypertrophy, mitochondrial de-energization and destructive changes in microcirculatory bloodstream.

Conclusion. In a long-term period of experimental renovascular hypertension, ANP and BNP have a positive effect on AP level falling up to the initial one due to ANP and BNP release on day 30 of the experiment. The efficiency of natriuretic peptides acting as a regulatory component in primary hypertension formation depends on arterial hypertension genesis.

  1. Baertschi A.J., Monnier D., Schmidt U., Levitan E.S., Fakan S., Roatti A. Acid prohormone sequence determines size, shape, and docking of secretory vesicles in atrial myocytes. Circ Res 2001; 89(3): E23–E29, http://dx.doi.org/10.1161/hh1501.095715.
  2. Marei H.E. Fine structural and immunohistochemical localization of cardiac hormones (ANP) in right atrium and hypothalamus if the white rat. Eur J Morphol 2002; 40: 37–41, http://dx.doi.org/10.1076/ejom.40.1.0037.
  3. Krylova M.I. Chromogranin A: immunocytochemical localization in secretory granules of frog atrial cardiomyocytes. Tsitologiya 2007; 49(7): 538–543.
  4. Rakhcheeva M.V., Bugrova M.L., Mukhina I.V., Zhabereva A.S. Atrial natriuratic peptide and experimental vasorenal hypertension in rats. Patologicheskaya fiziologiya i eksperimental’naya terapiya 2010; 4: 31–33.
  5. de Bold A.J. Thirty years of research on atrial natriuretic factor: historical background and emerging concepts. Can J Pharmacol 2011; 89: 527–531, http://dx.doi.org/10.1139/y11-019.
  6. Ogawa T., de Bold A. The heart as an endocrine organ. Endocr Connect 2014; 3(2): R31–R44, http://dx.doi.org/10.1530/EC-14-0012.
  7. Gurevitch M.A., Mravyan S.R., Veselova T.E. Significance of the system of atrial natriuretic peptides in heart failure and hypertension. Kardiologiia 2003; 9: 81–87.
  8. Liu R.T., Xiao H.L., Guo H.L., Qui D.G., Yin H.H., Wang Z.R. Expression of A-type atrial natriuretic peptide receptor in the kidneys of renovascular hypertension rats and its implication. Sichuan Da Xue Xue Bao Yi Xue Ban 2005; 36(6): 776–778.
  9. Irzmański R., Barylski M., Banach M., Piechota M., Kowalski J., Cierniewski C., Pawlicki L. The concentration of atrial and brain natriuretic peptide in patients with idiopathic hypertension. Med Sci Monit 2007; 13(10): CR449–CR456.
  10. Saliba Y., Chouery E., Mégarbané A., Jabbour H., Farès N. Microalbuminuria versus brain natriuretic peptide in cardiac hypertrophy of hypertensive rats. Physiol Res 2010; 59(6): 871–880.
  11. Sun Y., Deng T., Lu N., Yan M., Zheng X. B-type natriuretic peptide protects cardiomyocytes at reperfusion via mitochondrial calcium uniporter. Biomed Pharmacother 2010; 64(3): 170–176, http://dx.doi.org/10.1016/j.biopha.2009.09.024.
  12. Maksimov V.F., Korostyshevskaya I.M., Kurganov S.A., Markel A.L., Rudenko N.S., Jakobson G.S. Changes of right atrial myoendocrine cells during hypertension and after arterial pressure decrease. Tsitologiya 2014; 56(10): 725–734.
  13. Bugrova M.L., Abrosimov D.А., Yakovleva E.I., Baskina О.S., Ermolin I.L. The study on atrial natriuretic peptide of cardiomyocytes in a remote postperfusion period in experiment. Sovremennye tehnologii v medicine 2013; 5(4): 39–44.
  14. Mussalo H. Cardiovascular autonomic regulation in patients with sustained hypertension of different etiology and severity. Doctoral dissertation. Kuopio University Publications; 2003.
  15. Kawarada O., Yokoi Y., Morioka N., Takemoto K. Renal artery stenosis in cardio- and cerebrovascular disease: renal duplex ultrasonography as an initial screening examination. Circ J 2007; 71(12): 1942–1947, http://dx.doi.org/10.1253/circj.71.1942.
  16. Mukhin N.A., Fomin V.V., Moiseev S.V., et al. Ischemic renal disease (atherosclerotic renovascular hypertension), a clinical variant of disseminated atherosclerosis and a cause of chronic renal insufficiency. Vestnik RAMN 2008; 11: 24–33.
  17. Kharin S.N., Krandycheva V.V. Renal artery stenosis technique to model renovascular hypertension in rats. Bulleten’ eksperimental’noj biologii i mediciny 2004; 7: 118–120.
  18. Rakhcheeva M.V. Rol' predserdnogo i mozgovogo natriyureticheskikh peptidov v regulyatsii arterial'nogo davleniya pri vazorenal'noy gipertenzii u krys. Avtoref. dis. ... kand. biol. nauk [The role of atrial and brain natriuretic pepties in arterial pressure regulation in renovascular hypertension in rats. Abstract for the Dissertation of Candidate of Biological Sciences]. Moscow; 2009.
  19. Rakhcheeva M.V., Bugrova M.L., Mukhina I.V., Zhabereva A.S. The role of atrial natriuretic peptide in regulation of arterial pressure in two kidney one renal artery ligation in rats. Vestnik Nizhegorodskogo gosudarstvennogo universiteta im. N.I. Lobachevskogo 2009; 6(1): 132–136.
  20. Maksimov V.F., Korostyshevskaya I.M., Markel A.L., Filyushina E.E., Jakobson G.S. Cardiac natriuretic peptides and hypertension: experimental study. Vestnik RAMN 2013; 1: 4–9.
  21. Rakhcheeva M.V., Bugrova M.L. Reproportion of A- and B-type granules containing atrial and brain natriuretic peptides in rat atrial myocytes under renovascular hypertension. Tsitologiya 2010; 8: 629–633.
  22. Mikroskopicheskaya tekhnika [Microscopy technique]. Pod red. Sarkisova D.S., Perova Yu.L. [Sarkisov D.S., Perov Yu.L. (editors)]. Moscow: Meditsina; 1996; 544 p.
  23. Bugrova М.L., Yakovleva Е.I., Abrosimov D.А. The relationship of synthesis intensity, accumulation and secretion of natriuretic peptide of atrial myocytes with cardiac rhythm regulation in rats in early postperfusion period. Sovremennye tehnologii v medicine 2012; 3: 26–30.
  24. Sudarikova Yu.V., Bakeeva L.E., Tsyplenkova V.G. Energy dependent alterations of human cardiomyocytes mitochondria ultrastructure in alcoholic heart disease. Arhiv patologii 1999; 2: 15–20.
  25. Korostyshevskaya I.M., Maksimov V.F., Kurganov S.A. Ultrastructural estimation facilities of atrial cardiomyocyte secretory activity. Tsitologiya 2013; 55(8): 539–547.
  26. Sperelakis N., Forbs M.S. Ul’trastruktura miokarda mlekopitayushchikh. V kn.: Fiziologiya i patofiziologiya serdtsa. Tom I [Mammalian myocardial ultrastructure. In: Cardiac physiology and pathophysiology. Vol. I]. Moscow; 1990; p. 15–64.
  27. Wang J., Liu Z., Feng X., Gao S., Xu S., Liu P. Tumor suppressor gene ING3 induces cardiomyocyte hypertrophy via inhibition of AMPK and activation of p38 MAPK signaling. Arch Biochem Biophys 2014; 562: 22–30, http://dx.doi.org/10.1016/j.abb.2014.08.007.
  28. Bugrimova M.A., Savina N.M., Vanieva O.S., Sidorenko B.A. Brain natriuretic peptide as marker and factor of prognosis in chronic heart failure. Kardiologiia 2006; 1: 51–57.
  29. Langenickel T., Pagel I., Höhnel K., Dietz R., Willenbrock R. Differential regulation of cardiac ANP and BNP mRNA in different stages of experimental heart failure. Amer J Physiol Heart Circ Physiol 2000; 278(5): H1500–H1506.
  30. Vesely D.L. Discovery of new cardiovascular hormones for the treatment of congestive heart failure. Cardiovasc Hematol Disord Targets 2007; 7(1): 47–62, http://dx.doi.org/10.2174/187152907780059128#sthash.aO3kug5A.dpuf.
Galkina М.V., Baskina О.S., Bugrova М.L. The Study of Synthesis, Accumulation and Release Processes of Atrial and Brain Natriuretic Peptides in Experimental Renovascular Hypertension. Sovremennye tehnologii v medicine 2015; 7(2): 33, https://doi.org/10.17691/stm2015.7.2.04


Journal in Databases

pubmed_logo.jpg

web_of_science.jpg

scopus.jpg

crossref.jpg

ebsco.jpg

embase.jpg

ulrich.jpg

cyberleninka.jpg

e-library.jpg

lan.jpg

ajd.jpg

SCImago Journal & Country Rank